Literature DB >> 31163417

Histopathology and Cytopathology of Neuroendocrine Tumors and Carcinomas of the Breast: A Review.

Robert Y Osamura1,2, Naruaki Matsui3, Misa Okubo4, Lan Chen5, Andrew S Field6,7.   

Abstract

Neuroendocrine tumors (NET) and carcinomas (NEC) of the breast are rare diseases, but NEC has attracted attention in both cytopathology and surgical pathology because of its specific management and prognosis. Fine-needle aspiration biopsy (FNAB) cytology can make the diagnosis in many cases particularly with high-grade NEC, with definitive diagnosis based on histopathology and immunohistochemistry. This review describes the characteristics of the disease based on the WHO classification 2012 and recent literature and -includes discussion related to the International Academy of Cytology Yokohama System of Reporting Breast FNAB -cytology.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Breast carcinoma; Carcinoid; Chromogranin A; Fine-needle aspiration biopsy cytology; Neuroendocrine; Synaptophysin

Mesh:

Year:  2019        PMID: 31163417     DOI: 10.1159/000500705

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  3 in total

Review 1.  Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature.

Authors:  Yukinori Ozaki; Sakiko Miura; Ryosuke Oki; Teppei Morikawa; Keita Uchino
Journal:  Cancers (Basel)       Date:  2021-12-31       Impact factor: 6.639

2.  Syntaxin-1 and Insulinoma-Associated Protein 1 Expression in Breast Neoplasms with Neuroendocrine Features.

Authors:  Sándor Turkevi-Nagy; Ágnes Báthori; János Böcz; László Krenács; Gábor Cserni; Bence Kővári
Journal:  Pathol Oncol Res       Date:  2021-10-26       Impact factor: 3.201

3.  The Effect of the Extent of Neuroendocrine Differentiation on Cytopathological Findings in Primary Neuroendocrine Neoplasms of the Breast.

Authors:  Burcu Guzelbey; Ezgi Hacihasanoglu; Canan Kelten Talu; Yasemin Cakir; Mehmet A Nazli
Journal:  J Cytol       Date:  2021-11-22       Impact factor: 1.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.